Research

Pembrolizumab Plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma (LARA): A Multicentre, Single-Arm, Phase 2 Trial (The LANCET Oncology, Feb 2026)

A multinational study led by Principal Investigator A/Prof. David Tan and collaborators from Singapore and South Korea has demonstrated encouraging results for patients with recurrent clear cell ovarian and endometrial

Pembrolizumab Plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma (LARA): A Multicentre, Single-Arm, Phase 2 Trial (The LANCET Oncology, Feb 2026) Read More »

Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer (Cell Metabolism Nov 2025)

Authors Zhengwei Wu , Zhenxun Wang , Seow Qi Ng , Jessica Alice Lidster , Paul Schwerd-Kleine , Zi Jin Cheryl Phua , Kai Lay Esther Peh , Yin Ying

Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer (Cell Metabolism Nov 2025) Read More »

Pragmatic Interventions to Boost Surveillance Mammogram Uptake Among an Overdue Population A Randomized Clinical Trial (JAMA Internal Medicine, Nov 2025)

Authors Soo-Chin Lee, Sasidharan Swarnalatha Lucky, Junxian Zhu, Samuel Ow, Lukas Loh, Jun Hui Tan, Siew Eng Lim, Zarinah Hairom, Shivan Mehta 6, Bee-Choo Tai, Boon-Cher Goh Abstract Led by

Pragmatic Interventions to Boost Surveillance Mammogram Uptake Among an Overdue Population A Randomized Clinical Trial (JAMA Internal Medicine, Nov 2025) Read More »

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone (JCI, July 2025)

Authors: Valeria Cancila, Giorgio Bertolazzi, Allison S.Y. Chan, Giovanni Medico, Giulia Bastianello, Gaia Morello, Daniel Paysan, Clemence Lai, Liang Hong, Girija Shenoy, Patrick W. Jaynes, Giovanna Schiavoni, Fabrizio Mattei, Silvia

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone (JCI, July 2025) Read More »

Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin’s Lymphoma (JCO Precision Oncology, September 2025)

Treating patients whose non-Hodgkin’s lymphoma (NHL) has come back or stopped responding to therapy remains very difficult. Many eventually run out of standard treatment options. A team led by Dr.

Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin’s Lymphoma (JCO Precision Oncology, September 2025) Read More »

A Multi-task Domain-adapted Model to Predict Chemotherapy Response from Mutations in Recurrently Altered Cancer Genes (iScience, March 2025)

Aishwarya Jayagopal1, 7 ∙ Robert J. Walsh2,7 ∙ Krishna Kumar Hariprasannan1 ∙ Ragunathan Mariappan1 ∙ Debabrata Mahapatra6 ∙ Patrick William Jaynes3 ∙ Diana Lim4 ∙ David Shao Peng Tan2,3,5 ∙ Tuan Zea Tan3 ∙ Jason J. Pitt3 ∙ Anand D. Jeyasekharan2,3   Vaibhav Rajan1, 8 1. Department of Information Systems and Analytics, School of Computing, National University of Singapore, Singapore 117417, Singapore

A Multi-task Domain-adapted Model to Predict Chemotherapy Response from Mutations in Recurrently Altered Cancer Genes (iScience, March 2025) Read More »